DDInter283 DDInter105
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Cangrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Cangrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Cangrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Cangrelor {u} may lead to a major life threatening interaction when taken with {v} Alteplase
Cangrelor {u} may lead to a major life threatening interaction when taken with {v} Tinzaparin
Cangrelor may cause a minor interaction that can limit clinical effects when taken with Turmeric
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Cangrelor may lead to a major life threatening interaction when taken with Alteplase
Cangrelor may lead to a major life threatening interaction when taken with Tinzaparin